The Next Great Cosmetic Drug?

Before you go, we thought you'd like these...
Before you go close icon

This episode of The Motley Fool's Market Checkup drills down on the days hottest headlines, including more biotech buyout rumors, a hot new biotech start-up, and a new cosmetic drug.

In this video, health-care analyst David Williamson discusses a potential new solution to the double chin. Shares of Kythera (Nasdaq; KYTH) soared 25% on the news of a successful phase 3 trial for ATX-101, the sole drug in its pipeline.

Watch Market Checkup and find out more about the exciting cosmetic drug space, including a closer look at Botox maker Allergan , and whether investors should jump aboard the Kythera bandwagon. 

Stocks for a wealthy retirement
It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report, "3 Stocks That Will Help You Retire Rich," not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.

Follow David on Twitter: @MotleyDavid.

The article The Next Great Cosmetic Drug? originally appeared on

David Williamson has no position in any stocks mentioned.  Follow David on Twitter: @MotleyDavid Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool owns shares of Microsoft. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

People are Reading